Yüklüyor......
Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
Psoriasis is a chronic immune-mediated inflammatory condition, affecting 2–3% of the population. In recent years, advent of biologics, including secukinumab, have been a major advancement in the management of difficult-to-treat plaque psoriasis. However, high cost of biologics is often a deterrent,...
Kaydedildi:
| Yayımlandı: | Indian J Dermatol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer - Medknow
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6537682/ https://ncbi.nlm.nih.gov/pubmed/31148865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijd.IJD_548_18 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|